|View printer-friendly version|
Xtant Medical Announces First Surgical Use of OsteoSelect® PLUS DBM Putty
BELGRADE, Mont., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical implantation of OsteoSelect PLUS Demineralized Bone Matrix (DBM) Putty, developed by its wholly owned subsidiary, Bacterin International, Inc.
OsteoSelect PLUS is a next-generation DBM putty, comprised of OsteoSelect DBM Putty and demineralized cortical chips, designed to provide superior handling for surgeon end users during surgery. Dr. Ali Araghi, DO, Director of the Spine Division at The CORE Institute was the first surgeon to utilize OsteoSelect® PLUS DBM Putty in a spinal fusion procedure.
"OsteoSelect PLUS is aligned with Xtant’s commitment to patient safety and superior clinical outcomes," stated Dan Goldberger, CEO of Xtant. "OsteoSelect PLUS provides a sterile grafting solution to meet the needs of surgeons and expands our offering in the DBM market space."
OsteoSelect PLUS was developed in response to surgeon demand. Utilizing surgeon input for design allowed Bacterin to create an additional first class, bone graft substitute in the DBM space and strengthen its comprehensive product portfolio.
About Xtant Medical Holdings
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Important Cautions Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to successfully integrate the acquisition of X-spine; the ability of the Company's sales force to achieve expected results; the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash flow; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Contact: COCKRELL GROUP 877.889.1972 firstname.lastname@example.org cockrellgroup.com